SPINEWAY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.855 EUR | +6.86% |
|
-18.40% | -87.43% |
| 17/04 | Spineway: punished despite a solid first quarter | CF |
| 16/04 | Spineway SA Announces Revenue Results for the First Quarter of 2024 | CI |
| Sales 2022 | 8.53M 9.12M 761M | Sales 2023 | 11.36M 12.14M 1.01B | Capitalization | 711K 760K 63.42M |
|---|---|---|---|---|---|
| Net income 2022 | -3M -3.21M -268M | Net income 2023 | -6M -6.42M -535M | EV / Sales 2022 | - |
| Net cash position 2022 | 4.08M 4.37M 364M | Net Debt 2023 | 814K 870K 72.59M | EV / Sales 2023 | - |
| P/E ratio 2022 * |
-
| P/E ratio 2023 |
-
| Employees | 54 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 2.55% |
More Fundamentals
* Assessed data
More news
More news
| 1 day | +6.86% | ||
| 1 week | -18.40% | ||
| Current month | -37.60% | ||
| 1 month | -47.42% | ||
| 3 months | -96.08% | ||
| 6 months | -98.43% | ||
| Current year | -87.43% |
1 week
0.80
1.04
1 month
0.801.65
Current year
0.8030.00
1 year
0.801 962.00
3 years
0.80152 000.00
5 years
0.801 000 000.00
10 years
0.801 000 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
Stéphane Le Roux
CEO | Chief Executive Officer | 63 | 28/05/28 |
| Director of Finance/CFO | - | 27/20/27 | |
Sandrine Carle
PRN | Corporate Officer/Principal | - | 07/11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Weiguang Guo
BRD | Director/Board Member | 68 | - |
Stéphane Le Roux
CEO | Chief Executive Officer | 63 | 28/05/28 |
Joseph Brigneaud
BRD | Director/Board Member | 45 | 13/17/13 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 0.855 | +6.86% | 60,065 |
| 25/24/25 | 0.8001 | -9.08% | 155,740 |
| 24/24/24 | 0.88 | -8.39% | 120,731 |
| 23/24/23 | 0.9606 | -6.72% | 35,606 |
| 22/24/22 | 1.03 | -1.72% | 79,406 |
Real-time Euronext Paris, April 26, 2024 at 09:05 pm IST
More quotes
Spineway designs, produces, and sells spinal column implants and surgical instruments. The group offers spinal systems, cervical and lumbar cages, cervical plates, bone substitutes, etc.
Net sales are distributed geographically as follows: France (27.8%), Europe (21.4%), Latin America (29.8%), Asia (16.1%) and the Middle East and Africa (4.9%).
Calendar
29/04/2024
- Q4 2023 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.855
EUR
Average target price
1.8
EUR
Spread / Average Target
+110.53%
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -87.43% | 760K | |
| -2.31% | 187B | |
| -3.20% | 106B | |
| -5.04% | 66.9B | |
| +0.20% | 49.45B | |
| +17.29% | 48B | |
| +4.06% | 40.84B | |
| +2.07% | 26.48B | |
| +2.36% | 26.25B | |
| +12.96% | 24.62B |
- Stock Market
- Equities
- ALSPW Stock
